The epidermal growth factor receptor (EGFR/c-ErbB1/HER1) is overexpressed in many cancers including breast, ovarian, endometrial, and non-small cell lung cancer. An EGFR specific imaging agent could facilitate clinical evaluation of primary tumors and/or metastases. To achieve this goal we designed and synthesized a small array of fluorine containing compounds based on a 3-cyanoquinoline core. A lead compound, 16, incorporating 2 0 -fluoroethyl-1,2,3-triazole was selected for evaluation as a radioligand based on its high affinity for EGFR kinase (IC 50 = 1.81 ± 0.18 nM), good cellular potency (IC 50 = 21.97 ± 9.06 nM), low lipophilicity and good metabolic stability. 'Click' labeling afforded [ 
Introduction
Epidermal growth factor receptor (EGFR/c-ErbB1/HER1) is overexpressed in breast, ovarian and other human cancers.
1,2 EGFR along with the other three members of the HER family (HER2, HER3 and HER4) is a transmembrane glycoprotein with an extracellular ligand-binding domain, a transmembrane domain, and an intracellular domain with tyrosine kinase activity. EGFR is activated by binding to a variety of ligands including EGF, amphiregulin and TGF-a. 3 Once activated it is believed to undergo homo-or heterodimerization followed by activation of the intrinsic protein tyrosine kinase, autophosphorylation and activation of intracellular signal transduction pathways such as phosphatidylinositol-3-kinase (PI3K)/AKT and ras/raf/MEK/MAPK. 4, 3, 5 Blocking EGFR activity therefore appears to be a promising strategy in the treatment of cancer. Various anti-EGFR therapies have been developed; these include monoclonal antibody inhibitors like Cetuximab (IMC-C225) which is currently in use for the treatment of colorectal and head and neck cancers and in clinical trials for metastatic breast cancer 6, 7 and an arsenal of ATP competitive small molecules designed to inhibit the intracellular tyrosine kinase activity. 8 Certain compounds in this class have already been approved for clinical use (Gefitinib/Iressa, 9 Erlotinib/Tarceva 10 ) whilst others are under preclinical or clinical investigation [e.g., Neratinib, pelitinib (1, Fig. 1 )]. 11, 12 Molecular imaging techniques, such as PET (Positron Emission Tomography) have the potential to provide insights into EGFR biology. Potentially, PET with EGFR probes can non-invasively determine whether the target protein is overexpressed in a specific 0968 -0896/$ -see front matter Ó 2010 Elsevier Ltd. All rights reserved. doi:10.1016/j.bmc.2010.08.004 take in A431 tumors although a significant uptake in the liver was observed, partly due to the dissociation of the 64 Cu from the DOTA chelator. 14, 15 Initial attempts to develop small molecule imaging agents focused on the introduction of radiohalogens into reversible EGFR inhibitors based on a 4-anilinoquinazoline core. 13, [16] [17] [18] These showed promise in vitro but displayed inadequate signal to noise ratios for PET radioimaging in animal models, attributable to their relatively high lipophilicity (i.e., Log P) and rapid washout from cells by intracellular ATP. More recent reports by VanBrocklin et al., 19 Mishani et al. [20] [21] [22] [23] [24] and Neumaier and co-workers 25 have described the evaluation of 11 C, 124 I and 18 F radioligands based on irreversible EGFR inhibitors in which an electrophilic function is incorporated at C-6 of the quinazoline core. These derivatives bind covalently to the Cys 773 located in the tyrosine kinase binding pocket of EGFR thus preventing washout by intracellular ATP and increasing potency. 26 However, despite their resistance to washout and improved in vitro inhibition profiles, radioligands of this type have thus far displayed rapid metabolic degradation 20 and/or low specific tumor uptake. 27, 22 The only probe that has been evaluated in vivo by imaging in tumor bearing animals, quinazoline 2 ( Fig. 1) , gave non-ideal image quality, at least in part due to these features. 25 The aim of the work described here was the synthesis and biological evaluation of 18 F radiolabeled irreversible imaging agents based on the known 3-cyanoquinoline irreversible inhibitor, pelitinib (EKB-569, 1, Fig. 1) . 28, 29 To enable selection of the most suitable candidate radiotracer we designed a small array of fluorine containing derivatives with the intention of selecting the best candidate on the basis of high affinity to the receptor and ease of labeling. 18 F was chosen in preference to 11 C because it's long half-life time (t 1/2 = 109.8 min) allows more elaborate radiosynthesis and permits washout of non-specific binding. It was planned to introduce the 18 F-containing prosthetic group at the last stage of the synthesis so as to maximize the radiochemical yield of the process.
For quinazoline-based inhibitors (e.g., Neumaier's quinazoline 2, Fig. 1 ), a key interaction with the EGFR binding site is the indirect hydrogen bonding of N-3 of the quinazoline core to Thr 830 mediated by a molecule of water. 29 However, molecular modeling studies indicate that in 3-cyanoquinolines (e.g., pelitinib 1, Fig. 1 ), the 3-cyano group hydrogen bonds directly to Thr 830 without the involvement of a water molecule. 29 We speculated that this latter, probably more entropically favored, interaction might be exploited in a derived imaging agent to allow for higher uptake into the tumor and result in more specific imaging signal. In line with the design criteria applied previously to irreversible quinazoline-based tracer candidates, we wanted to retain an aniline moiety at C-4 to optimally occupy the active site hydrophilic pocket and a Michael acceptor (incorporating a tethered amine) at C-6 to covalently bind to Cys 773. 29 Consequently, it was decided that compound 1 would be modified by the addition of fluorine containing groups at the terminus of the C-6 Michael acceptor (with minimal structural perturbation) or at the C-7 position (which points outside the active site and does not appear to play an important role in binding). In the interest of maximizing resistance to metabolic degradation we were also interested in exploring the reportedly increased stability of Michael acceptors modified with secondary rather than tertiary amines. 30 
Results

Chemistry
Pelitinib (EKB-569, 1) was synthesized by the procedure of Wissner et al. 29, 31 via the key 3-cyanoquinoline intermediate 3.
This latter compound also provided the starting point for the synthesis of three potential labeling precursors 6, 8, and 10, which incorporate modified C-6 Michael acceptor units. Compound 6 incorporates a methylamine unit in place of the dimethylamine unit found in pelitinib (1) so as to allow label introduction via alkylation or reductive amination. This derivative was prepared by AlMe 3 mediated amidation with methyl (E)-4-(tert-butoxycarbonylmethylamino)-but-2-enoate 4 (47%) 32 followed by Boc removal using 10% concd HCl in dioxane (78%). Compound 8 incorporates a Boc-propargylamine unit in place of the dimethylamine unit found in pelitinib (1) so as to allow label introduction via copper(I) catalyzed Huisgen 1,3-dipolar cycloaddition (the 'click' reaction). [33] [34] [35] [36] This derivative was prepared by AlMe 3 mediated amidation with ethyl (E)-4-(tert-butoxycarbonyl-prop-2-ynyl-amino)-but-2-enoate 7 (see Section 4, 68%). Compound 10 incorporates a terminal alkyne in place of the dimethylaminomethyl unit found in pelitinib (1) so as to allow an alternative mode of label introduction via 'click' cycloaddition. This derivative was prepared by AlMe 3 mediated amidation with methyl (E)-pent-2-en-4-ynoate 9 (20%) 37 (Scheme 1).
Derivatization of N-methyl amine 6 in a manner amenable to the introduction of an 18 F radiolabel was explored by alkylation and via reductive amination. Alkylation of amine 6 with 1-fluoro-2-mesyloxy ethane (11) in CH 2 Cl 2 gave the N-fluoroethyl product 12 in 33% yield following difficult chromatographic separation from unidentified by-products. Alternatively, reductive amination of 4-fluoro benzaldehyde by quinoline 6 was achieved using NaB-H(OAc) 3 and gave the 4-fluorobenzyl product 13 in 21% yield following rapid chromatography (Scheme 2). Derivatization of N-Boc-propargylamine 8 and enyne containing quinoline 10 in a manner amenable to the introduction of an 18 an HCl salt following Boc removal using HCl in 1,4-dioxane. Similarly, enyne 10 reacted with azide 14 to give fluorotriazole-containing quinoline 15 in 32% yield. In both cases, the final yields were compromised by the apparent instability of the Michael acceptor precursors under the reaction conditions (Scheme 3). Quinoline 20 was designed as a direct analogue of quinoline 6 but containing a 2-fluoroethoxy group in place of the C-7 ethoxy group. The synthesis route started from quinoline 17, 29, 31 which is an intermediate in the Wissner synthesis of pelitinib (EKB-569, 1), and was not designed for direct translation into a labeling method but rather as the most convenient entry for SAR purposes. The C-7 ethyl ether in quinoline 17 was removed by treatment with BBr 3 and the resulting quinoline 18 was alkylated with 1-fluoro-2-mesyloxy ethane (11) under basic conditions followed by acetamide hydrolysis to give 7-(2-fluoroethoxy)quinoline 19. AlMe 3 mediated amidation with methyl (E)-4-(tert-butoxycarbonyl-methyl-amino)-but-2-enoate 4 and Boc removal by treatment with HCl in 1,4-dioxane gave the target quinoline 20 as its HCl salt (Scheme 4). None of the aforementioned 'cold' procedures were optimized as this was not required in order to prepare sufficient material for subsequent evaluation (see below). 
Radiochemistry
Biology
A key design goal is the introduction of radiolabeled motifs without significant detriment to EGFR inhibitory affinity (asurrogate for binding) relative to the starting quinoline 1. Therefore, assessment of the EGFR tyrosine kinase activity of control quinolines 1 together with quinolines 6, 12, 13, 15, 16, 20, and 21 was carried out using a cell-free kinase activity inhibition assay as detailed in Section 4. Given the encouraging inhibitory EGFR kinase activity of the compound series in the cell-free system, we examined cellular activity-the ability of the compounds to be transported across cell membranes and to inhibit EGFR autophosphorylation-in highly EGFR expressing A431 cells. 41 Following a protocol previously reported by Rabindran et al., 11 we measured the potency of the compounds to inhibit autophosphorylation of EGFR after 3 h of drug incubation and a further 2 h of washing with drug free medium. Due to the washing steps, the protocol permits the effect of irreversible binding activity to be quantified. Typical immunoblots demonstrating inhibition of EGFR autophosphorylation are shown in Figure 2 . In these studies the drug did not inhibit the expression of total EGFR protein. The inhibitory activity of compounds 1, 6, 12, 13, 16, 20, and 21 on cellular EGFR autophosphorylation, (Table 1) translated well from that assessed in the cell-free system, with IC 50 values in the low nanomolar range. Interestingly, no cellular activity was apparent when dosing with quinoline 15. Furthermore, the cellular activity of quinoline 21 was in the low nanomolar range indicating that, although potent, the high affinity of this alkyne in the kinase assay did not directly translate into cellular activity.
As a consequence of the in vitro screening, quinoline 16 was selected for further development because of its high binding affinity, structural novelty, and the ease of click radiolabeling. The in vivo evaluation of the imaging agent [
18 F]16 focused on the assessment of its metabolic stability and its ability to be taken up into a EGFR expressing xenograft, A431, in animals. Non-specific binding plagued development of earlier generation radiotracers (quinazolines) for imaging EGFR. 22 We initially assessed two of the likely reasons for non-specific binding-poor metabolic stability and poor phar- Figure 3 and the results are summarized in Table 2 . At 2 min, only parent compound was observed in liver and plasma. A low level more polar peak was seen in liver at 30 and 60 min and a similar radioactive metabolite was seen in plasma. This metabolic stability data demonstrates that the parent radiotracer [ 18 F]16 remains a major component of both liver and plasma even at 60 min post injection; indicative of relatively good stability in vivo.
The 60 min tissue biodistribution A431 tumor bearing mice, expressed as tissue to blood ratios, has been measured and the results are shown in Figure 4 . Tumor (A431 xenograft) uptake was approximately fourfold higher than that of muscle (%ID/g in tumor = 0.082 ± 0.022 and %ID/g in muscle = 0.018 ± 0.004, see Supplementary data, Table S1 ). Low radioactivity was also observed in other organs including bone, brain, and heart. The low uptake in bone suggests that the radiotracer does not undergo defluorination. The radiotracer appeared to be eliminated via both the hepatobiliary and renal routes, as the highest tissue radioactivities were found in the gallbladder and the urine. Elimination of the radiotracer into the gut may also account for the high radioactivity in the early part of the intestine (Fig. 4) .
We further assessed the potency of compound showed more rapid washout of the radiotracer from HCT116 tumors. Significant radiotracer localization was also seen in the abdominal region consistent with the biodistribution data. The PET data were corroborated by ex vivo tumor uptake and western blot analysis of EGFR protein content of the two tumor types ( Fig. 5 ). There was a fourfold higher uptake in A431 xenografts compared to HCT116 xenografts.
Discussion and conclusion
Previous PET imaging studies with irreversible inhibitors of EGFR have suggested that selectivity and metabolic stability are likely to be key attributes of radiotracers if they are to display good uptake by tumors and give good image quality. 13 With this in mind, we selected the 3-cyanoquinoline therapeutic agent pelitinib (1), first reported by Tsou et al., 29, 31, 43 as a template on which to introduce an 18 F label. The 3-cyanoquinoline core, as indicated in the introduction, was chosen in preference to the quinazoline core because it was hoped that it might engender higher uptake into the tumor and result in more specific imaging signal. The C-4 aniline and C-6 aminocrotonylamide moieties were retained to ensure selectivity for EGFR and irreversible binding to the active site Cys 773 via Michael addition, respectively. 29 A small array of 19 F containing 3-cyanoquinolines was therefore synthesized (compounds 12, 13, 15, 16, and 20) and these compounds were tested for their ability to inhibit the intracellular tyrosine kinase autophosphorylation activity of EGFR. The fluorine containing groups were introduced onto both the Michael acceptor moiety and the C-7 ether position of the quinoline core. Previous studies 29, 31 have indicated some tolerance for substitution at these sites, which made the C-6 and C-7 positions attractive for modification in the present investigation. The synthetic routes developed to prepare the C-6 derivatives were designed such that they would be amenable to preparation of the corresponding 19 F product in order to evaluate its properties. The eight compounds were screened for their EGFR tyrosine kinase activity inhibition using BPDQ as positive control. The non-fluorinated quinolines 1, 6, and 21 were also screened; compound 1 was used as a standard and compounds 6 and 21 were the potential radiochemical precursors for those fluorinated quinolines most likely to be translated into imaging agents.
We assessed these latter compounds in order to better understand the potential impact of residual impurities in an eventual radiopharmaceutical formulation. As expected, in the cell-free kinase activity inhibition assay, the sub-nanomolar binding affinity showed by quinolines 1 and 6 was retained in quinolines 12 and 13 despite the increased bulk of the tertiary amine substituents. Surprisingly, the activity of the alkynecontaining quinoline 21 was in the picomolar range, possibly because of secondary interactions of the alkyne group with the binding site of the enzyme, a feature unfortunately not retained in compound 16. Nevertheless, the low nanomolar affinity of compound 16 was considered sufficient to allow further in vivo characterization of EGFR related activities. The slightly higher IC 50 of compound 15 may be attributable to the replacement of the tertiary amine, which acts as internal base, with the significantly less basic triazole ring (vide infra). Finally, quinoline 20, designed to be a direct analogue of quinoline 6, but containing a 2-fluoroethoxy group in place of the C-7 ethoxy group, showed the same activity as compound 6 confirming that the C-7 group is not involved in the binding with the EGFR tyrosine kinase enzyme. With these preliminary encouraging results in hand, the candidate compounds were screened for their ability to inhibit autophosphorylation in the human epithelial carcinoma A431 cell line. All the compounds were active at nanomolar concentrations except for compound 15 and the positive control BPDQ. Compounds 12, 13, 16, and 21 were, however, 10-fold less active than reference compounds 1 and 6.
The lack of activity of compound 15 might be accounted for by its inability to cross the cell membrane, although its physicochemical properties are comparable with the other members of the series. Alternatively, the lack of activity of compound 15 in cells might be a consequence of it having a more reversible interaction with the kinase, as the methodology we employed for measuring cellular activity (with washing steps) permits mainly irreversible inhibition to be quantified. This would be consistent with the lack of activity of BPDQ which is known to be a reversible inhibitor of EGFR. 40 A reversible interaction of compound 15 with EGFR kinase is possible since replacement of the amine group at the terminus of the Michael acceptor with a nitrogen atom contained within a triazole ring system may prevent the Michael reaction of the Cys 773 thiol from occurring; this would result in loss of activity in the cellular assay. The low basicity of the triazole nitrogen and/or the lack of conformational flexibility of this group could well be preventing the Michael acceptor from reacting efficiently. In particular, the aromatic nature of the triazole ring combined with the sp 2 hybridisation state of the N-3 atom ensures that its basicity is likely $10
9
-fold lower than that of the secondary/tertiary amines. Moreover, the triazole ring has an extended planar p-electron system conjugated to the amide carbonyl group and consequently will have a significant barrier to rotation to give the correct orientation in which this nitrogen lone pair can assist with general base catalysis of the attack of the Cys 773 thiol at the c position of the enamide unit. We interpret the lower activity of compounds 12, 13, 16, and 21 relative to compounds 1 and 6 as suggesting that bulkier groups on the amine of the Michael acceptor have a negative effect on the cellular activity. This effect is particularly apparent for compound 21 whose activity decreases 2000-fold in the cell relative to its activity in the cell-free assay. This may be due to side reactions of the alkyne moiety with the cell surface which could partially prevent its penetration into the cell, although no specific evidence for this was obtained. Compound 20, where the Michael acceptor has not been modified, showed comparable activity to compounds 1 and 6.
Quinoline 16 was then selected for further development as a first generation 3-cyanoquinoline imaging agent. This compound balanced high binding affinity in vitro, structural novelty, and a radiosynthesis method via efficient 'click' chemistry. Cognizant of the importance of a favorable metabolic profile, we decided to test compound 16 for its stability in mouse and human liver microsomes in comparison with compound 6. Interestingly, after 60 min of incubation, only the parent compound was detected by HPLC (data not shown). The absence of metabolites is consistent with the notion that secondary amine substituted Michael acceptors display relatively high metabolic stability (cf. tertiary amine analogues). 30 The C-7 ethoxy group also appears to be relatively Although high non-specific localization was seen in the elimination organs, the uptake into the tumor was clearly visible, particularly for A431. Specificity of radiotracer uptake was demonstrated by the higher uptake of the radiotracer in high EGFR expressing A431 tumor xenografts compared to low EGFR expressing HCT116 tumor xenografts. The high level of radioactivity in the intestine is of particular concern as this would preclude use of this tracer for imaging, for example, colorectal cancer but should not limit its application for other EGFR overexpressing cancers, for example, breast cancer.
In conclusion, compound [ 18 F]16 represents a first generation, 3-cyanoquoline-based selective EGFR radioimaging agent. The 3-cyanoquinoline core and C-6 Michael acceptor bearing a triazole functionalized secondary amine terminus appear to confer greater metabolic stability than has been previously reported for related EGFR probes. The biodistribution profile in normal tissues, the selectivity of radiotracer uptake in A431 versus HCT116 and the ability to detect A431 tumors in animal models by PET imaging certainly encourage further investigations into the use of this reagent for EGFR imaging. The initial results reported herein suggest that modifications of the structure of compound [ 18 F]16 designed to modulate the pharmacokinetic properties will be necessary to further improve uptake into the tumor and reduce non-specific binding. Further studies are currently ongoing in our laboratories.
Experimental section
Chemistry and radiochemistry
Solvents were distilled as follows: THF and Et 2 O over Na-benzophenone ketyl, toluene over Na, and CH 2 Cl 2 over CaH 2 . Reagents were used as commercially supplied unless otherwise stated and handled in accordance with COSHH regulations. Flash chromatography (FC) was carried out on Silica gel (BDH Silica Gel for FC). NMR spectra were recorded at 400 MHz on a Bruker AV-400 or Bruker DX-400 instrument or at 500 MHz on a Brucker AV-500 instrument. Chemical shifts (d) are given in parts per million (ppm) as referenced to the appropriate residual solvent peak. The reference for 19 F NMR is CFCl 3 (= 0 ppm). Broad signals are assigned as br. 13 
HPLC methods
(a) Preparative radio-HPLC was carried out on a Beckman System Gold equipped with a Bioscan Flowcount FC-3400 PIN diode detector (Lablogic) and a linear UV-200 detector (wavelength 254 nm). A Phenomenex Luna C18 150 mm Â 10 mm HPLC column and a isocratic mobile phase of water and 20% acetonitrile (0.085% H 3 PO 4 ) and flow rate 3 mL/min. (b) Analytical radio-HPLC was carried out as above but using a Bioscan Flowcount FC3200 sodium iodide/PMT gamma detector (Lablogic), a Thermo Spectra SERIES UV150 (wavelength 254 nm), and a Phenomenex Luna 50 mm Â 4.6 mm (3 lm) column with an isocratic mobile phase of water and 22% acetonitrile (0.1% TFA), flow rate 1 mL/min. H NMR spectral data were consistent with those previously reported.
Synthesis
(E)-4-(tert-Butoxycarbonyl-prop-2-ynylamino)-but-2-enoic acid methyl ester (7)
4-Bromo methylcrotonate (1 g, 5.6 mmol) was dissolved in dry THF (10 mL) and propargyl amine (961 lL, 14 mmol) was added dropwise at À20°C. The resulting mixture was stirred at À20°C for 4 h then cooled to À65°C. 
General procedure for the synthesis of compounds 5, 8, 10, and Boc-20
The amino quinolines 3 or 19 (1 equiv) and the Michael acceptor 4, 7 or 9 (1.5 equiv) were suspended and sonicated in dry CH 2 Cl 2 (0.06 M) and AlMe 3 (2.0 M solution in hexane, 2 equiv) was added dropwise at rt. The mixture was stirred at rt and monitored by TLC until the starting quinoline had disappeared. The mixture was quenched with a saturated solution of NaHCO 3 and the phases were separated. The aqueous layer was extracted twice with equal volumes of CH 2 Cl 2 and the combined organic layers washed with equal volume of brine and dried over MgSO 4 . The crude mixture was purified by FC or plate silica gel TLC. (13) . Quinoline 6 (50 mg, 0.10 mmol) was suspended in dichloroethane (0.3 mL) and p-fluorobenzaldehyde (12 lL, 0.11 mmol) and acetic acid (10 lL) were added dropwise at rt.
After 30 min, NaBH(OAc) 3 (32 mg, 0.15 mmol) was added and the mixture was stirred 14 h at rt. The mixture was quenched with a saturated solution of NaHCO 3 (1 mL) and extracted with CH 2 Cl 2 (3 Â 2 mL). The combined organic layers were dried over MgSO 4 . After purification by plate silica TLC (CH 2 Cl 2 /MeOH, 20:1; R f = 0.37), the title compound 13 was obtained (12 mg (18) . The quinoline 17 (500 mg, 1.15 mmol) was suspended in dry CH 2 Cl 2 (50 mL) and BBr 3 (1.0 M in CH 2 Cl 2 , 5.7 mL, 5.7 mmol) was added dropwise at rt. The mixture was stirred 14 h and quenched with water (20 mL). The yellow precipitate was collected, washed with water (50 mL), and dried in vacuo. The title compound 18 was obtained as a yellow solid (166 mg, 40%) and used in the next step without further purification. 
4.3.4.4.
6-Amino-4-(3-chloro-4-fluorophenylamino)-7-(2-fluoroethoxy)-quinoline-3-carbonitrile (19) . The quinoline 18 (25 mg, 0.06 mmol) was heated with K 2 CO 3 (41.4 mg, 0.30 mmol) and 2-mesyloxy-1-fluoroethane (17 mg, 0.12 mmol) in DMF (1 mL) at 70°C overnight. The mixture was cooled at rt, water (1 mL) was added and yellow solid was collected, washed with water (3 mL) and Et 2 O (3 mL) and dried in vacuo. The yellow solid was then refluxed in water (0.5 mL) and concd HCl (0.5 mL) for 2.5 h then cooled at rt. The crude mixture was concentrated under reduced pressure, dissolved in water (2 mL) and neutralized with K 2 CO 3 . Quinoline 19 (8 mg, 53%) was collected as a yellow solid. 
Radiochemistry
Under an atmosphere of nitrogen, a buffered solution (sodium phosphate buffer, pH 6.0, 250 mM) of sodium ascorbate (50 lL, 8.7 mg, 43.2 lmol) was added to a Wheaton vial (3 mL) containing an aqueous solution of copper(II) sulfate (50 lL, 1.7 mg pentahydrate, 7.0 lmol). After 1 min, a solution of alkyne 21 (2.1 mg, 4.4 lmol) in MeCN/water, 1:1 (50 lL) was added followed by dis- 
EGFR tyrosine kinase enzyme inhibition assay
The inhibitory activity of quinolines 1, 6, 12, 13, 15, 16, 20 , and 21 against EGFR kinase activity was measured by a time resolved fluorescence assay (DELFIA, Perkin-Elmer Life Sciences, Boston, MA, USA). The compounds were dissolved in DMSO and diluted in DMSO to give final concentrations of 0.0001-100,000 lg/mL.
EGFR protein (E-3641, Sigma) was incubated with the compounds in a kinase buffer for 15 min at rt in accordance with manufacturer's instructions (DELFIA Tyrosine kinase kit; Perkin-Elmer). After 15 min at rt the kinase reaction was initiated by addition of 25 lM ATP, 25 mM MgCl 2 , and 0.25 lM/L of biotinylated poly(Glu,
